The Mount Sinai Conference on the pharmacotherapy of schizophrenia

Stephen R. Marder; Susan M. Essock; Alexander L. Miller; Robert W. Buchanan; John M. Davis; John M. Kane; Jeffrey Lieberman; Nina R. Schooler

doi:10.1093/oxfordjournals.schbul.a006926

The Mount Sinai Conference on the pharmacotherapy of schizophrenia

Stephen R. Marder, Susan M. Essock, Alexander L. Miller, Robert W. Buchanan, John M. Davis, John M. Kane, Jeffrey Lieberman, Nina R. Schooler

Psychiatry

Research output: Contribution to journal › Article › peer-review

106 Scopus citations

Abstract

This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.

Original language	English (US)
Pages (from-to)	5-16
Number of pages	12
Journal	Schizophrenia bulletin
Volume	28
Issue number	1
DOIs	https://doi.org/10.1093/oxfordjournals.schbul.a006926
State	Published - 2002

Keywords

Antipsychotics
Clozapine
Evidence-based practice
Schizophrenia
Tardive dyskinesia

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1093/oxfordjournals.schbul.a006926

Fingerprint Dive into the research topics of 'The Mount Sinai Conference on the pharmacotherapy of schizophrenia'. Together they form a unique fingerprint.

Cite this

@article{dd16342947474f10aef8a075960c1a80,

title = "The Mount Sinai Conference on the pharmacotherapy of schizophrenia",

abstract = "This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.",

keywords = "Antipsychotics, Clozapine, Evidence-based practice, Schizophrenia, Tardive dyskinesia",

author = "Marder, {Stephen R.} and Essock, {Susan M.} and Miller, {Alexander L.} and Buchanan, {Robert W.} and Davis, {John M.} and Kane, {John M.} and Jeffrey Lieberman and Schooler, {Nina R.}",

year = "2002",

doi = "10.1093/oxfordjournals.schbul.a006926",

language = "English (US)",

volume = "28",

pages = "5--16",

journal = "Schizophrenia Bulletin",

issn = "0586-7614",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - The Mount Sinai Conference on the pharmacotherapy of schizophrenia

AU - Marder, Stephen R.

AU - Essock, Susan M.

AU - Miller, Alexander L.

AU - Buchanan, Robert W.

AU - Davis, John M.

AU - Kane, John M.

AU - Lieberman, Jeffrey

AU - Schooler, Nina R.

PY - 2002

Y1 - 2002

N2 - This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.

AB - This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.

KW - Antipsychotics

KW - Clozapine

KW - Evidence-based practice

KW - Schizophrenia

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=0035988520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035988520&partnerID=8YFLogxK

U2 - 10.1093/oxfordjournals.schbul.a006926

DO - 10.1093/oxfordjournals.schbul.a006926

M3 - Article

C2 - 12047022

AN - SCOPUS:0035988520

VL - 28

SP - 5

EP - 16

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

SN - 0586-7614

IS - 1

ER -